Flat-rate pricing · Discounts available · All-inclusive pricing No commitment required · Cancel anytime Prescription included · Online questionnaire, no video call · No lab work required · Free consultation FDA-registered 503B pharmacy · Multiple pharmacy options · Third-party tested Free overnight shipping · Supplies included · Discreet packaging Money-back guarantee Tirzepatide, Semaglutide Auto-renewing plans Mixed additive-free options Not available in all statesProvider Plans Monthly Plan Tirzepatide Monthly
Beaker (503A) Apothecary Pharma (503B)
Dose Your Supply Your Price Your Supply Avg/mo Your Value 2.5mg/wk 10mg/mo $389.00 10mg $389 $38.90/mg 5.0mg/wk 20mg/mo $389.00 20mg $389 $19.45/mg 7.5mg/wk 30mg/mo $389.00 30mg $389 $12.97/mg 10.0mg/wk 40mg/mo $389.00 40mg $389 $9.72/mg 12.5mg/wk 50mg/mo $389.00 50mg $389 $7.78/mg 15.0mg/wk 60mg/mo $389.00 60mg $389 $6.48/mg
Starter Plan Tirzepatide Starter
Starter Sale: $100 off $289/avg
Beaker (503A) Apothecary Pharma (503B)
Dose Your Supply Your Price Your Supply Avg/mo Your Value 2.5mg/wk 10mg/mo $289.00 $389.00 10mg $289 $28.90/mg 5.0mg/wk 20mg/mo $289.00 $389.00 20mg $289 $14.45/mg 7.5mg/wk 30mg/mo $289.00 $389.00 30mg $289 $9.63/mg 10.0mg/wk 40mg/mo $289.00 $389.00 40mg $289 $7.22/mg 12.5mg/wk 50mg/mo $289.00 $389.00 50mg $289 $5.78/mg 15.0mg/wk 60mg/mo $289.00 $389.00 60mg $289 $4.82/mg Sale price included · Converts To Monthly Plan After Term
Provider Details Prescription Included Yes
Telehealth Included Yes
Online-Only Option Yes
Skip Labs Yes
Credit Money-Back Guarantee Starter Sale: up to $100 off Sale: $50 off
Insurance Accepted No
HSA/FSA Accepted Yes
Financing Available Not Disclosed
Sale Yes
LegitScript Certified Yes
HIPAA Compliant Yes
Mobile App Not Disclosed
Supplies Included Cold-Packed
Free Shipping Yes
Expedited Shipping Yes
Discreet Packaging Yes
Offers Tirzepatide Yes
Offers Semaglutide Yes
Offers Brand No
Other Treatments Yes
Phone Not Disclosed
Address Not Disclosed
Provider Notes Compliance Compounded medications are not FDA-approved and are prescribed only when a clinician determines a compounded preparation produces a significant difference for the patient.
The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.